Supplemental Figures S1-S8 from The Estrogen Receptor Cofactor SPEN Functions as a Tumor Suppressor and Candidate Biomarker of Drug Responsiveness in Hormone-Dependent Breast Cancers

Autor: Mark Basik, Olga Aleynikova, Sylvie Mader, David Laperrière, Saima Hassan, Dana Keilty, Marguerite Buchanan, Patricia N. Tonin, Alexander Klimowicz, Anthony Magliocco, Isabelle Sirois, Catherine Chabot, Aline Mamo, Luca Cavallone, Stéphanie Légaré

SPEN is mutated in T47D cells (S1); SPEN is down-regulated and mutated in breast cancer (S2); SPEN regulates cell growth and survival (S3); SPEN knockdown in triple negative breast cancer cell lines limits proliferation (S4); SPEN regulates cell deat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f2b44563d7e144bbd73c4387332a821
https://doi.org/10.1158/0008-5472.22404962.v1

Supplemental Tables S1-S5 from The Estrogen Receptor Cofactor SPEN Functions as a Tumor Suppressor and Candidate Biomarker of Drug Responsiveness in Hormone-Dependent Breast Cancers

Autor: Mark Basik, Olga Aleynikova, Sylvie Mader, David Laperrière, Saima Hassan, Dana Keilty, Marguerite Buchanan, Patricia N. Tonin, Alexander Klimowicz, Anthony Magliocco, Isabelle Sirois, Catherine Chabot, Aline Mamo, Luca Cavallone, Stéphanie Légaré

Clinical data (S1); Expression levels of SPEN and PGR as evaluated with DNA microarrays (S2); IC50 values of SPEN-overexpressing T47D clones, SPEN-silenced MCF-7 clones and their respective controls (S3); Loss of heterozysity assessment using polymor

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::699c356f26eb4675670e5757a6d16f5b
https://doi.org/10.1158/0008-5472.22404959

The Estrogen Receptor Cofactor SPEN Functions as a Tumor Suppressor and Candidate Biomarker of Drug Responsiveness in Hormone-Dependent Breast Cancers

Autor: Isabelle Sirois, Dana Keilty, Olga Aleynikova, Catherine Chabot, Alexander C. Klimowicz, Marguerite Buchanan, Patricia N. Tonin, Aline Mamo, Sylvie Mader, Stéphanie Légaré, David Laperrière, Anthony M. Magliocco, Saima Hassan, Mark Basik, Luca Cavallone

Publikováno v: Cancer Research. 75:4351-4363

The treatment of breast cancer has benefitted tremendously from the generation of estrogen receptor-α (ERα)–targeted therapies, but disease relapse continues to pose a challenge due to intrinsic or acquired drug resistance. In an effort to deline

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75602e66fb6d069e6b20063dc3658da3
https://doi.org/10.1158/0008-5472.can-14-3475

The Role of Ceroid Lipofuscinosis Neuronal Protein 5 (CLN5) in Endosomal Sorting

Autor: Aline Mamo, Stephane Lefrancois, Santiago Costantino, Karine Dumaresq-Doiron, Felix Jules

Publikováno v: Molecular and Cellular Biology. 32:1855-1866

Mutations in the gene encoding CLN5 are the cause of Finnish variant late infantile Neuronal Ceroid Lipofuscinosis (NCL), and the gene encoding CLN5 is 1 of 10 genes (encoding CLN1 to CLN9 and cathepsin D) whose germ line mutations result in a group

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::088f3be90ea9beaf85177ef0b48af5ee
https://doi.org/10.1128/mcb.06726-11

An integrated genomic approach identifies ARID1A as a candidate tumor-suppressor gene in breast cancer

Autor: Catherine Chabot, Patricia N. Tonin, Sukru Tuzmen, Ewa Przybytkowski, Mark Basik, Spyro Mousses, K. Malcolm, Luca Cavallone, Olli Kallioniemi, Aline Mamo, Cristiano Ferrario, Saima Hassan, Henrik Edgren, Olga Aleynikova

Publikováno v: Mamo, A, Cavallone, L, Tuzmen, S, Chabot, C, Ferrario, C, Hassan, S, Edgren, H, Kallioniemi, O, Aleynikova, O, Przybytkowski, E, Malcolm, K, Mousses, S, Tonin, P N & Basik, M 2012, ' An integrated genomic approach identifies ARID1A as a candidate tumor-suppressor gene in breast cancer ', Oncogene, vol. 31, no. 16, pp. 2090-2100 . https://doi.org/10.1038/onc.2011.386

Tumor-suppressor genes (TSGs) have been classically defined as genes whose loss of function in tumor cells contributes to the formation and/or maintenance of the tumor phenotype. TSGs containing nonsense mutations may not be expressed because of nons

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::038b83a14ea0fe2f0a98fbab99bbc05e
https://doi.org/10.1038/onc.2011.386